Antibiotics in the Pipeline for Treatment of Infections due to Gram-Negative Organisms

被引:0
作者
Nicole C. Vissichelli
Michael P. Stevens
机构
[1] Virginia Commonwealth University,Division of Infectious Diseases, Department of Internal Medicine
来源
Current Treatment Options in Infectious Diseases | 2019年 / 11卷
关键词
Gram-negative; Antibiotic development; Antimicrobial resistance;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:115 / 144
页数:29
相关论文
共 538 条
[11]  
Ghazi IM(2018)Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa Int J Antimicrob Agents 51 629-635
[12]  
Monogue ML(2018)Two for the price of one: emerging carbapenemases in a returning traveller to New York City Lancet Infect Dis 18 285-295
[13]  
Tsuji M(2017)Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae Case Rep Infect Dis 2017 1-5
[14]  
Nicolau DP(2017)Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial Antimicrob Agents Chemother 61 e00449-e00417
[15]  
Ito A(2017)Successful treatment of Klebsiella pneumoniae harboring a Klebsiella pneumoniae carbapenemase isolated from lumbar wound infection and blood in a patient with hardware retention Int J Infect Dis 59 118-123
[16]  
Kohira N(2017)Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections Int J Antimicrob Agents 49 770-773
[17]  
Bouchillon SK(2017)Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients Antimicrob Agents Chemother 61 e02097-e02016
[18]  
West J(2016)Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation Clin Infect Dis 63 1615-1618
[19]  
Rittenhouse S(2015)Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections Antimicrob Agents Chemother 60 1328-1335
[20]  
Sader HS(2014)Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections: Table 1 Clin Infect Dis 59 51-61